The main scenarios associated with reduced VEGF expression are the use of anti-VEGF drugs, such as for the treatment of neoplasms, and preeclampsia, caused by a disproportionate increase in soluble fms-like tyrosine kinase-1 (produced in the process of inadequate placentation), which binds to circulating VEGF and placental growth factor, thus preventing them from interacting with their endothelial receptors (18). Here, VEGFA is linked to neoplasm.